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with	at	 least	one	value	higher	 than	 the	99th	 percentile	upper	
reference	 limit	 (URL)	 AND	 symptoms	 consistent	 with	
ischaemia	 OR	 dynamic	 ECG	 changes	 	 (including	 >1mm	 ST	




(or	 5	 x	 the	 baseline	 value	 if	 this	 is	 higher	 than	 the	 URL)	 in	
combination	with	any	of	(a)	evidence	of	prolonged	ischaemia	




reflow,	 embolisation,	 or	 (d)	 imaging	 evidence	 of	 new	 loss	 of	
viable	myocardium	or	new	regional	wall	motion	abnormality.	
Following	CABG,	Troponin	(T	or	I)		>	10	x	99th	percentile	URL	
(or	 10	 x	 the	baseline	 value	 if	 this	 is	 higher	 than	 the	URL)	 in	
combination	with	any	of	the	following:	(i)	new	pathological	Q	
waves	or	 (ii)	 angiographically	documented	new	graft	or	new	
native	 coronary	 artery	 occlusion	 or	 (iii)	 imaging	 evidence	 of	










outcome	measure	 of	 periprocedural	myocardial	 injury	 and	will	 also	

















symptoms	 or	 signs	 of	 HF,	 where	 there	 is	 a	 documented	
diagnosis	 of	 HF	 and	 the	 patient	 receives	 initiation	 or	
intensification	of	treatment	for	HF.	Initiation	or	intensification	
of	treatment	includes	at	least	one	of	the	following:	increase	in	
oral	 diuretic	 dose	 or	 addition	 of	 another	 oral	 diuretic,	
intravenous	diuretic	 therapy,	 intravenous	 vasoactive	 therapy	
(vasodilator,	inotrope	or	vasopressor),	mechanical	circulatory	
support	 (MCS)	 (including	 intra-aortic	 balloon	pump,	 Impella,	





of	 treatment	 as	 defined	 above.	 Prolongation	 of	 hospital	
admission	in	patients	who	have	prophylactic	pre-PCI	insertion	
of	a	MCS	should	not	be	recorded	as	having	a	HF	hospitalization	













¥! Overt	 bleeding	 plus	 haemoglobin	 drop	 ≥50g/L	
(provided	haemoglobin	drop	is	related	to	bleed)	
¥! Cardiac	tamponade	





¥! Intracranial	 haemorrhage	 (does	 not	 include	
microbleeds	 or	 haemorrhagic	 transformation;	 does	
include	intraspinal)	
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¥! Probable	 fatal	 bleeding:	 no	 autopsy	 or	 imaging	
confirmation,	but	clinically	suspicious	
Type	5b	





PCI	 group:	 any	 unplanned	 target	 vessel	 or	 non-target	 vessel	
revascularisation	by	PCI	or	CABG	following	index	PCI,	excluding	
provisional	 staged	 PCI	 (with	 plan	 documented	 at	 the	 index	
procedure).		
OMT	group:	any	revascularisation	by	PCI	or	CABG	
	
	
		
	
